Abstracts tagged "Miscellaneous Rheumatic and Inflammatory Diseases"

Abstract Number: 1942 • ACR Convergence 2022
Maybe Silent: Spine Disease in Chronic Recurrent Multifocal Osteomyelitis, Clinical Features, Risk Factors, and Red Flags
Shima Yasin¹, T. Shawn Sato², Emma Leisinger², Aleksander Lenert², Yongdong (Dan) Zhao³ and Polly Ferguson¹, ¹University of Iowa Carver College of Medicine, Iowa City, IA, ²University of Iowa, Iowa City, IA, ³University of Washington, Redmond, WA
Background/Purpose: Chronic recurrent multifocal osteomyelitis (CRMO) is a female predominant autoinflammatory bone disease. The average age at disease onset is 9-10 years. The majority have…
Abstract Number: 0563 • ACR Convergence 2022
High-Dimensional Immunophenotyping with Mass Cytometry Reveals Unique Immune Cell Aberrations in Patients with Undiagnosed Inflammatory and Autoimmune Diseases
Alisa Mueller¹, Takanori Sasaki², Joshua Keegan¹, Jennifer Nguyen¹, Alec Griffith¹, Elizabeth Feig¹, Alice Horisberger³, Ye Cao¹, Gregory Keras¹, Lauren Briere⁴, Laurel Cobban¹, Daimon Simmons¹, Juan Pallais¹, Jeffrey Sparks², V. Michael Holers⁵, Undiagnosed Diseases Network¹, David Sweetser⁴, Joel Krier¹, Joseph Loscalzo¹, James Lederer¹ and Deepak Rao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Harvard Medical School and Lausanne University Hospital, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵University of Colorado, Denver, CO
Background/Purpose: Few tools are available to evaluate the immune dysregulation in patients with severe autoimmune or inflammatory conditions that do not conform to well-defined rheumatologic…
Abstract Number: 2243 • ACR Convergence 2022
Patient Reported Outcomes from a Randomized Phase 3 Trial of Sarilumab in Polymyalgia Rheumatica
Vibeke Strand¹, Jennifer Sloane Lazar², Michael C Nivens³, Jingdong Chao⁴, Stefano Fiore⁵, Angeliki Giannelou⁶, Lita Araujo⁷ and Jerome Msihid⁸, ¹Stanford University School of Medicine, Stanford, CA, ²Sanofi, Delray Beach, FL, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, NY, ⁴Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, ⁵Sanofi, Bridgewater, NJ, ⁶Regeneron Pharmaceuticals, Inc., Hoboken, NJ, ⁷Sanofi, Cambridge, MA, ⁸Sanofi, Chilly-Mazarin, France
Background/Purpose: Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease in the elderly. The phase 3 SAPHYR trial (NCT03600818) assessed the efficacy and safety of…
Abstract Number: 0758 • ACR Convergence 2022
Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE)-like Syndrome After Immune Checkpoint Inhibition: A CanRIO Study
Azin Rouhi¹, Shahin Jamal², Marie Hudson³, Janet Pope⁴, Janet Roberts⁵, Alexandra Ladouceur³, Sara Hewitt⁶ and Carrie Ye¹, ¹University of Alberta, Edmonton, AB, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³McGill University, Montréal, QC, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Dalhousie University, Halifax, NS, Canada, ⁶Western University, London, ON, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have shown great promise in the treatment of different malignancies. The use of ICIs has been associated with toxicities that…
Abstract Number: 0771 • ACR Convergence 2022
The Use of a bDMARD or tsDMARD for the Management of Rheumatic irAE Under Checkpoint Inhibitors: An Observational Study
Fanny De La Fuente¹, Rakiba Belkhir², Julien Henry³, Chi Duc Nguyen⁴, Thao Pham⁵, Vincent GERMAIN⁶, Pierre-Edouard Gavand⁷, Céline Labadie¹, Claire Brière⁸, Ambre Lauret⁸, Thierry Cardon⁹, Gaël Mouterde¹⁰, Isabelle Bonnet¹¹, Léa Rouxel¹², Marie Truchetet¹, Thierry schaeverbeke¹³, Christophe Richez¹⁴ and Marie Kostine¹⁵, ¹Bordeaux University Hospital, Bordeaux, France, ²Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, ³Department of Rheumatology, University Paris-Saclay, Hospital Bicêtre, Le Plessis Robinson, Ile-de-France, France, ⁴Bethune Hospital, Bethune, France, ⁵Aix-Marseille univ, APHM, Marseille, France, ⁶Pau Hospital, Rheumatology, Pau, France, Pau, France, ⁷Rhena Clinic, Strasbourg, France, ⁸Intercommunal Creteil Hospital, Créteil, France, ⁹Lille University Hospital, Lille, France, ¹⁰Lapeyronie Hospital, Montpellier, France, ¹¹University Paris-Saclay, Hospital Bicêtre, Bicêtre, France, ¹²Arcachon Hospital, Arcachon, France, ¹³CHU de Bordeaux, Bordeaux, France, ¹⁴Université de Bordeaux, Bordeaux, France, ¹⁵Pellegrin Hospital, University Hospital of Bordeaux, Rheumatology, Bordeaux, France
Background/Purpose: Rheumatic immune related adverse events (irAEs) are observed in about 5 to 10% of cancer patients receiving checkpoint inhibitors (ICIs), with inflammatory arthritis (IA)…
Abstract Number: 0776 • ACR Convergence 2022
Expert Clinical Management of Immune-related Inflammatory Arthritis: Results from a Multicenter International Expert Survey
Sebastian Bruera¹, Maria Suarez-Almazor² and mar Riveiro-Barciela³, ¹Baylor College of Medicine, Houston, TX, ²MD Anderson Cancer Center, Houston, TX, ³Hospital Universitari Vall d'Hebron, Barcelona, Spain
Background/Purpose: The management of inflammatory arthritis related to immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICI) is challenging. Arthritis can become chronic and require…
Abstract Number: 0810 • ACR Convergence 2022
Analysis of Factors Associated with Good Therapeutic Response to Immunosuppressive Drugs in Patients with Non-infectious Uveitis: A Survival Analysis
María Paula Álvarez Hernández¹, Alejandro Gómez Gómez², Lara Borrego Sanz³, Rosalía Méndez Fernández³, Pedro Arriola Villalobos³, Esperanza Pato Cour⁴, David Díaz Valle³ and Luis Rodriguez-Rodriguez⁴, ¹Hospital Clínico San Carlos, Madrid, Spain, ²Hospital Infanta Sofia, Rheumatology, San Sebastián de los Reyes, Madrid, Spain, ³Instituto de Investigación Sanitaria San Carlos, Ophthalmology, Madrid, Spain, ⁴Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain
Background/Purpose: Non-infectious uveitis (NIUs) encompass a varied group of inflammatory diseases affecting the uvea and adjacent tissues, with evidence suggesting an immune-mediated cause. A correct…
Abstract Number: 0820 • ACR Convergence 2022
Therapeutic Practices and Outcomes of Chronic Sarcoidosis Arthropathy in the United States: A Nationwide Registry Study
Diala Alawneh¹, Moustafa Younis², Bashar Alzghoul², Christian Ascoli¹, Tricha Shivas³, Mary McGowan³, Khaldoon Alawneh⁴, Divya Patel², Israel Rubinstein¹ and Nadera Sweiss¹, ¹University of Illinois at Chicago, Chicago, IL, ²University of Florida, Gainesville, FL, ³Foundation for Sarcoidosis Research, Chicago, IL, ⁴Jordan University of Science and Technology, Irbid, Jordan
Background/Purpose: Chronic arthropathy is a rare manifestation of sarcoidosis reported in only 0.2% of patients. However, treatment is challenging because no general consensus regarding appropriate…
Abstract Number: 1109 • ACR Convergence 2022
High Interleukin-13 Level Is Associated with Disease Stability in Interstitial Lung Disease
Elena Joerns¹, David Karp¹, Jeffrey Sparks², Traci Adams¹, Una Makris³ and Chad Newton¹, ¹UT Southwestern, Dallas, TX, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Interstitial lung disease (ILD) is a disease of lung parenchyma manifesting with inflammation and fibrosis. Interstitial lung disease (ILD) is a frequent complication of…
Abstract Number: 1110 • ACR Convergence 2022
Solving Sarcoidosis: A Transcriptome-based Meta-analysis of Clinical Sarcoidosis Studies Illustrates Shared Pathophysiology, Identifies Candidate Biomarkers and Suggests a Therapeutic Mechanism of JAK Inhibition
Ingrid Lindquist¹, James T. Rosenbaum² and Marcia Friedman³, ¹Oregon Health and Science University, Portland, OR, ²Legacy Devers Eye Institute, Portland, OR, ³Oregon Health and Science University, Division of Arthritis and Rheumatic Diseases, Portland, OR
Background/Purpose: Sarcoidosis is a systemic, non-caseating granulomatous disease driven by a dysregulated immune response to environmental antigens. A wide range of clinical manifestations coupled with…
Abstract Number: 1111 • ACR Convergence 2022
Sarcoidosis Rates in BCG-Vaccinated and Unvaccinated Young Adults: A Danish Register-Based Study
Matthew Baker¹, Emese Vágó², Suzanne Tamang³, Erzsébet Horváth-Puhó² and Henrik Sørensen², ¹Stanford University, Stanford, CA, ²Aarhus University Hospital, Aarhus, Denmark, ³Stanford Center for Population Health Sciences, Redwood City, CA
Background/Purpose: The inciting factor or antigen exposure that initiates sarcoidosis remains unknown. However, an infectious trigger such as Mycobacterium spp. or Propionibacterium acnes infection may…
Abstract Number: 1308 • ACR Convergence 2022
Prevalence and Therapeutic Practices of Osteoporosis in Sarcoidosis in the United States: A Nationwide Registry Study
Diala Alawneh¹, Moustafa Younis², Romesa Hassan¹, Bashar Alzghoul², Shiva Arami¹, Tricha Shivas³, Mary McGowan³, Khaldoon Alawneh⁴, Christian Ascoli¹ and Nadera Sweiss¹, ¹University of Illinois at Chicago, Chicago, IL, ²University of Florida, Gainesville, FL, ³Foundation for Sarcoidosis Research, Chicago, IL, ⁴Jordan University of Science and Technology, Irbid, Jordan
Background/Purpose: Patients with sarcoidosis are at an increased risk of developing osteoporosis due to the active inflammatory state and chronic corticosteroid use. Proper dosing of…
Abstract Number: 1669 • ACR Convergence 2022
Comparing the Safety and Effectiveness of Methotrexate, TNF and IL6 Inhibitors for the Treatment of Checkpoint Inhibitor Arthritis
Anne Bass¹, Noha Abdel-Wahab², Pankti Reid³, Jeffrey Sparks⁴, Cassandra Calabrese⁵, Deanna Jannat-Khah, DrPH, MSPH⁶, Diviya Rajesh⁶, Nilasha Ghosh⁶, Komal Mushtaq⁷, Farah Al Haj⁸, Adewunmi Falohun⁹, Lydia Gedmintas¹⁰, Lindsey MacFarlane¹¹, Senada Arabelovic¹¹, Adi Diab², Ami Shah¹², Clifton O. Bingham III¹³, Karmela Kim Chan⁶ and Laura C. Cappelli¹⁴, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²UT MD Anderson Cancer Center, Houston, TX, ³University of Chicago Medical Center, Chicago, IL, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Cleveland Clinic Foundation, Cleveland Heights, OH, ⁶Hospital for Special Surgery, New York, NY, ⁷Cleveland Clinic, Cleveland, OH, ⁸Sinai Grace Hospital/ Detroit Medical Center, Detroit, MI, ⁹MD Anderson Cancer Center, Houston, TX, ¹⁰Brigham and Women's Hospital, Boston, MA, ¹¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹²Johns Hopkins Rheumatology, Baltimore, MD, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitor associated arthritis (ICI-A) affects ∼4% of ICI-treated cancer patients and often persists. Given its long duration, it is important to identify…
Abstract Number: 0439 • ACR Convergence 2021
Predictors of Rheumatic Immune-related Adverse Events and de Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor-treatment for Cancer
Amy Cunningham-Bussel¹, Jiaqi Wang², Lauren Prisco³, Lily Martin², Kathleen Vanni², Alessandra Zaccardelli², Mazen Nasrallah⁴, Lydia Gedmintas², Lindsey MacFarlane⁵, Nancy Shadick⁶, Mark M. Awad⁷, Osama E. Rahma⁷, Nicole LeBoeuf⁸, Ellen Gravallese⁹ and Jeffrey Sparks², ¹Brigham and Women's, Brookline, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Pound Ridge, MA, ⁴MGH, Somerville, MA, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Brigham & Women's Hospital, Boston, MA, ⁷Dana-Farber Cancer Institute, Boston, ⁸Brigham and Women's Hospital, Department of Dermatology, Boston, MA, ⁹Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: Immune-related adverse events (irAEs) are a frequent and serious complication of immune checkpoint inhibitor (ICI) treatment for cancer, which can resemble primary rheumatic diseases.…
Abstract Number: 0621 • ACR Convergence 2021
Case Series of IgG4-related Disease in African American Patients at Two Large Academic Centers
Jonathan Thaler¹, Sunita Dia² and Florina Constantinescu², ¹MedStar Georgetown University Hospital, Washington, DC, ²Medstar Washington Hospital Center, Washington, DC
Background/Purpose: IgG4-related Disease (IgG4-rD) is a fibroinflammatory disease with highly variable manifestations that can be difficult to diagnose. Response to treatment with prednisone and/or rituximab…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].